Enzene appoints Norm Stoffregen to lead biologics manufacturing facility in US
03 September 2024 | News
Stoffregen brings a vast experience of building manufacturing businesses
Enzene Biosciences, a fully integrated contract development and manufacturing organisation (CDMO) with services spanning discovery, development and commercial supply, has announced the appointment of Norm Stoffregen as SVP, site head, and head of biologics manufacturing at the company’s new $50 million manufacturing facility in Hopewell, near Princeton, New Jersey, US.
As well as taking responsibility for Enzene’s global biologics business, Stoffregen will lead the final stages of work to commission the 54,000-square-foot facility. He will then lead ongoing operations at the site, where the company intends to transfer-in existing customers’ manufacturing projects and expand to add further bioreactor capacity, employing a workforce of 300 by the end of 2025.
Significantly, Stoffregen brings a vast experience of building manufacturing businesses, having worked in the area since 2015 when the Hopewell facility was owned by Bristol Myers Squibb (BMS).
Immediately prior to joining Enzene, Stoffregen was VP-site head at PTC Therapeutics, and before that held various roles of increasing responsibility at BMS and with other biotherapeutics/bioprocessing companies, where he amassed more than 20-years’ experience in leadership, quality assurance, and Chemistry, Manufacturing and Controls (CMC).
